Role of the microbiota–gut–heart axis between bile acids and cardiovascular disease - 27/04/24


Abstract |
Bile acid (BA) receptors (e.g., farnesoid X-activated receptor, muscarinic receptor) are expressed in cardiomyocytes, endothelial cells, and vascular smooth muscle cells, indicating the relevance of BAs to cardiovascular disease (CVD). Hydrophobic BAs are cardiotoxic, while hydrophilic BAs are cardioprotective. For example, fetal cardiac insufficiency in maternal intrahepatic cholestasis during pregnancy, and the degree of fetal cardiac abnormality, is closely related to the level of hydrophobic BAs in maternal blood and infant blood. However, ursodeoxycholic acid (the most hydrophilic BA) can reverse/prevent these detrimental effects of increased levels of hydrophobic BAs on the heart. The gut microbiota (GM) and GM metabolites (especially secondary BAs) have crucial roles in hypertension, atherosclerosis, unstable angina, and heart failure. Herein, we describe the relationship between CVD and the GM at the BA level. We combine the concept of the “microbiota–gut–heart axis” (MGHA) and postulate the role and mechanism of BAs in CVD development. In addition, the strategies for treating CVD with BAs under the MGHA are proposed.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Abbreviations : ASBT, BA, BDL, BKCa, BSEP, BSH, CA, cAMP, CDCA, CDVF, CHF, CKD, CM, CONV-R, CVD, CYP27A1, CYP7A1, DCA, eNOS, ERK, ET-1, FGF, FMT, FXR, GCA, GCDCA, GF, GM, GPBAR, GPCR, HF, HFD, ICP, ID, IGF-1, iNOS, KATP, LCA, LPS, LXR, MAPK, MCA, MGHA, MNLC, MPTP, MR, MRP, NTCP, OATP, OSTα/β, PAG, PKA, PKC, PXR, S1PR, SCFAs, TC, TCA, TCDCA, TGR5, TLR, TMA, TMAO, T-MCAs, TSBA, TUDCA, UA, UDCA, VDR, VEC, VSMC, β-AR
Keywords : Bile acids, Cardiovascular disease, Microbiota-gut-heart axis, Therapeutic strategy
Plan
Vol 174
Article 116567- mai 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?